Free Trial
NASDAQ:SANA

Sana Biotechnology Q1 2026 Earnings Results & Report

Sana Biotechnology logo
$2.36 -0.08 (-3.09%)
As of 12:17 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sana Biotechnology beat analyst earnings expectations in its Q1 2026 results, released May 11, 2026. The company reported EPS of -$0.14 versus the -$0.15 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Sana Biotechnology EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.15
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Sana Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sana Biotechnology Q1 2026 Earnings FAQ

Sana Biotechnology (NASDAQ:SANA) reported earnings of -$0.14 per share for Q1 2026, beating the consensus estimate of -$0.15. The report was announced on Monday, May 11, 2026.

Sana Biotechnology Earnings Headlines

Your Copy is on Hold (Claim it now)
James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.tc pixel
Sana Biotechnology: A Shot At Diabetes
See More Sana Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sana Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sana Biotechnology and other key companies, straight to your email.

About Sana Biotechnology

Sana Biotechnology (NASDAQ:SANA) is a clinical-stage biotechnology company founded in 2018 and headquartered in Seattle. It develops engineered cells intended to treat a range of diseases, including cancer, autoimmune disorders and conditions that may be addressed through cell replacement.

The company’s research focuses on modifying cells to improve their therapeutic properties, including approaches designed to help transplanted cells evade immune rejection. Its programs include engineered immune-cell therapies and cell-replacement treatments, such as work involving insulin-producing cells for type 1 diabetes. These are investigational programs, not approved products.

Sana conducts research and development in the United States, with locations including Seattle, South San Francisco and Cambridge. Its chief executive officer is Steve Harr.

View Sana Biotechnology Profile